Strasbourg, France & Schiphol, Netherlands, Apr 3, 2026 - (JCN Newswire) - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Bio B.V. ("NEC"), a wholly owned subsidiary of NEC Corporation (TSE: 6701), a leader in IT, network and AI technologies, announce the signing of a license agreement to advance the clinical development of TG4050, an individualized neoantigen therapeutic vaccine (INTV) in the adjuvant treatment of resected HPV-negative head and neck cancer.

TG4050 is an individualized immunotherapy based on an MVA viral vector incorporating neoantigens selected using NEC’s AI-enabled prediction platform. It is currently being evaluated in patients with head and neck cancer with the aim of preventing relapse and extend disease-free survival following surgery and adjuvant therapy. TG4050 is designed to stimulate and educate the immune system against a patient’s cancer using tumor-specific genetic mutations (neoantigens) targeting each patient’s unique tumor. These neoantigens are identified and selected using NEC’s proprietary platform, which applies advanced machine learning to select immunogenic mutations that are most likely to induce a strong immune response.

Under the terms of the license agreement, Transgene secures access to NEC’s AI-based neoantigen prediction platform for further development of TG4050 in the adjuvant treatment of resected HPV-negative head and neck cancer while conferring rights to enable Transgene’s further clinical development and to support commercialization and potential partnering of the program. NEC retains full ownership and operational control of its AI platform and will support Transgene to conduct further clinical activity.

NEC will receive a technology access fee of €2.5 million in Transgene shares following the signing (see below) and an additional €2.5 million in cash to be paid out in a series of tranches through early 2028. Additionally, a further payment will be milestone-based and a portion of such payment will be made in Transgene’ shares. NEC is also eligible to receive undisclosed additional consideration including development milestone payments, as well as a double-digit share of profits or licensing revenues.

"Building on the results of our long-standing collaboration and with the license to use NEC’s prediction platform, we are now in a strong position to pursue further development of TG4050, which will be informed by data from our ongoing Phase 2 trial. We are also pleased to welcome NEC as a shareholder of Transgene and appreciate their confidence as we work together to advance a treatment that has the potential to improve the outcomes for patients at risk of relapse in head and neck cancer," said Dr. Alessandro Riva, Chairman and CEO of Transgene.

Akira Kitamura, GM, AI Drug Development Division of NEC Corporation and CEO of NEC Bio, added, "This agreement is an important milestone in our partnership with Transgene and reflects NEC’s long-term commitment to the development of TG4050. This collaboration is a clear example of how NEC can bring differentiated AI capabilities to biopharma. The clinical data generated to date is encouraging and support the potential of TG4050 as a promising approach to reducing relapse risk in patients with head and neck cancer. We look forward to deepening our collaboration with Transgene and to realizing the full clinical and strategic potential of this partnership."

Capital increase

As indicated above, a €2.5 million portion of the access fee to be paid to NEC will be paid in Transgene shares. Transgene will thus issue 3,345,824 new shares to NEC Bio B.V. at a price of €0.7472 per share. This price corresponds to the volume-weighted average (VWAP) of the last five (5) closing prices of the Transgene shares on the regulated market of Euronext in Paris prior to signing. The new shares will represent 1.22% of the share capital of Transgene post issuance (and 0.98% of its voting rights)1.

The capital increase is carried out on the basis of the 22nd resolution of the Combined General Meeting of May 15, 2025. The new shares will be admitted to trading on the regulated market of Euronext in Paris as soon as they are issued and will be immediately assimilated to the existing Transgene shares (ISIN code FR0005175080).

The capital increase is expected to be completed by the end of April 2026.

(1) Based on today’s share capital and voting rights.Share

About TG4050

TG4050 is an individualized immunotherapy being developed in the treatment of resected HPV-negative head and neck cancer that is based on Transgene’s myvac® technology and powered by NEC’s longstanding artificial intelligence (AI) and machine learning (ML) expertise. This virus-based individualized neoantigen therapeutic vaccine (INTV) encodes neoantigens (patient-specific mutations) identified and selected by NEC’s Neoantigen Prediction System. The prediction system is based on more than two decades of expertise in AI and has been trained on proprietary data allowing it to prioritize and select the sequences that are predicted to be the most immunogenic sequences.

TG4050 is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens. This individualized immunotherapy is developed and produced for each patient.

About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company’s clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company’s lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The Company has other viral vector-based assets, including BT-001, an oncolytic virus based on the Invir.IO® viral backbone, which is in clinical development. The Company also conducts innovative discovery and preclinical work, aimed at developing novel immunotherapies.With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.Additional information about Transgene is available at: www.transgene.com
Follow us on social media: X: @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene

About NEC Corporation

The NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group’s approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society. For more information, please visit https://www.nec.com, follow us on Instagram, Facebook, and LinkedIn.

About NEC Bio

NEC Bio is the biotechnology arm of NEC Corporation, headquartered in the Netherlands, and focused on leveraging state of the art AI technologies to address world's most pressing healthcare challenges. Leveraging cutting-edge science, data, and innovation, NEC Bio is dedicated to developing personalized therapies designed to transform patient outcomes and improve quality of life globally. With a growing international footprint, NEC Bio includes subsidiaries such as NEC OncoImmunity in Oslo, Norway, and NEC Bio Therapeutics in Mannheim, Germany—each contributing specialized expertise across immunotherapy, precision medicine, and translational research. Together, these entities form a collaborative ecosystem committed to accelerating innovation from discovery to patient impact.To learn more, visit www.nec-bio.com and follow us on LinkedIn for the latest updates.

Disclaimer
This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results, regulatory authorities’ agreement with development phases, and development. The Company’s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document, available on the AMF website (http://www.amf-france.org) or on Transgene’s website (www.transgene.com). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

TOKYO, Mar 26, 2026 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701) announced that its FonesVisuas Test, an innovative blood test that predicts disease risk, is being offered by Royal Healthcare (*1), a Singapore-based medical institution and group company of Sojitz Corporation that combines the latest medical expertise with the art of hospitality.

Entrance of the Specialist Medical Centre                       Interior of the Specialist Medical Centre

According to the World Health Organization (WHO), the global rise in lifestyle-related diseases and dementia underscores the urgency for advanced predictive diagnostics (*2). Concurrently, the Organisation for Economic Co-operation and Development (OECD) iLibrary data has identified cancer and cardiovascular diseases as leading causes of mortality worldwide (*3), amplifying the urgency for proactive health management solutions.

Royal Healthcare is based in Singapore's medical hub, Novena, providing personalized, high-quality health screening services alongside customized medical experiences that prioritize efficiency and convenience for both local and international patients.

The addition of the FonesVisuas Test represents a significant advancement by analyzing proteins that reflect dynamic physiological changes. From just a small blood sample, the test can predict risks of developing conditions such as dementia, heart attack, lung cancer, chronic kidney disease, and prostate cancer over the next several years.

Royal Healthcare combines its services with conventional health checkups to guide individuals who are not yet ill but also not in optimal health toward lifestyle improvements. This approach aims to prevent future illness and enhance people's quality of life.

Looking ahead, NEC plans to expand provision of the FonesVisuas Test internationally, particularly in the APAC region, underscoring its commitment to advancing global healthcare standards.

(*1)https://royal-healthcare.com/
(*2)https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases https://www.who.int/news-room/fact-sheets/detail/dementia
(*3)https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2023_7a7afb35-en

About NEC

The NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group’s approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society.

For more information, please visit https://www.nec.com, and follow us on Instagram, Facebook, YouTube, and LinkedIn.

Kawasaki and Tokyo, Japan, Mar 16, 2026 - (JCN Newswire) - Fujitsu Japan Limited and Teikyo University Hospital today announced the start of a joint proof of concept aimed at strengthening regional medical collaboration. The initiative, which commenced on March 16, focuses on developing new information analysis and patient management mechanisms utilizing medical administration systems and electronic health record data. This will facilitate the prompt admittance of severely ill patients requiring hospitalization or surgery and a smooth transition back to primary care after discharge.

This joint experiment will implement the following initiatives for Teikyo University Hospital's regional medical collaboration operations:

1. Digitalization of Patient Workflow from Referral Acceptance to Discharge Coordination

By introducing AI-OCR and electronic paper for referral reception and discharge coordination, information from outside the hospital will be digitized. This will be seamlessly integrated with electronic health records and regional medical collaboration information systems, aiming to eliminate duplicate data entry and improve overall operational efficiency.

2. Verification of the Health Care Management Platform for Data-Driven Strategic Patient Acquisition

Based on data from medical accounting systems and electronic health records, Health Care Management Platform, an offering under Fujitsu Limited's Uvance business model which addresses societal challenges, will be used to visualize and analyze trends in referred patients and collaborating facilities in a timely manner. This will enable the identification of facilities where collaboration should be strengthened, and actual visits to these facilities will be conducted to enhance regional collaboration. Visit records and results will be registered and accumulated in Salesforce's Agentforce 360 Platform, aiming to utilize this information for analyzing referral performance and formulating strategies that comprehensively address the needs of collaborating facilities.

Figure: Patient workflow in regional medical collaboration and a joint proof of concept

Through this initiative, Teikyo University Hospital aims to reduce the administrative workload of its Medical Collaboration Office, which handles regional collaboration tasks, by 30%, while contributing to the provision of high-quality and prompt medical care and the optimization of medical resources for patients.

Moving forward, both parties will expand the scope of integration between this system and electronic health records to centrally manage the patient workflow, including treatment processes after referral acceptance. This will contribute to providing medical care to patients at more appropriate times and supporting decision-making for healthcare professionals, thereby improving hospital management and fostering regional medical collaboration.

Fujitsu Japan will leverage the insights from this joint experiment to enhance accuracy and add new functionalities to its offerings, supporting Teikyo University Hospital's digital transformation (DX) and the promotion of digital hospitals. Furthermore, under Uvance, Fujitsu Japan will drive the transformation of medical practice workflows through data and AI, advancing the establishment of a sustainable healthcare delivery system.

Teikyo University Hospital will systematize this mechanism as a model for realizing a data-driven regional healthcare system and promote its expansion to other medical institutions and regions. Through this initiative, the hospital also aims to further enhance the role and value of its Medical Collaboration Office, which serves as the hospital's public face, and build a foundation for the office to function as a hub for regional medical care, moving beyond its traditional role of handling referral reception and coordination.

Background

Japanese healthcare faces a challenging management environment due to a declining birthrate, an aging population, and rising material costs, while medical needs are becoming increasingly complex due to advancements in medical technology. To ensure sustainable healthcare, it is essential to strengthen collaboration between primary care physicians and specialists, ensuring patients are referred at appropriate times, receive advanced treatment, and are then referred back to their primary care physicians for ongoing care. This kind of regional medical collaboration is essential.

The Japanese government is also promoting medical DX and functional differentiation and collaboration within regions, establishing evaluations and incentives in the fiscal year 2026 medical fee revision.

As a specialized hospital in the Itabashi Ward region, Teikyo University Hospital accepts over 30,000 referred patients annually and has actively promoted regional collaboration through continuous lectures and visits to medical institutions. Regarding referred patient acceptance, the hospital receives approximately 200 calls daily from patients and medical institutions, utilizing up to eight lines at a time. A key challenge has been the time and burden placed on reception staff to coordinate referred patient acceptance, especially for urgent referrals and transfer requests from other medical institutions, often requiring consultation with doctors, leading to waiting times for outpatient appointments and hospitalization.

About Fujitsu

Fujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsu

Press Contacts
Fujitsu Limited
Public and Investor Relations Division
Inquiries

Kawasaki and Tokyo, Japan, Mar 9, 2026 - (JCN Newswire) - Fujitsu Limited and DT-Axis Co., Ltd. today announced the commencement of a collaboration aimed at advancing digital health. The two companies have signed a memorandum of understanding to provide comprehensive support for the development of Software as Medical Device (SaMD), including regulatory approval and sales, for research and development institutions, as well as medical device and pharmaceutical companies.

SaMD, such as therapeutic applications and AI-powered image diagnostics, are expected to contribute significantly to health promotion, preventive medicine, and treatment, with their development and medical device approval progressing globally. However, in Japan, even with promising research results and technologies applicable to SaMD, challenges remain in establishing a system design and development framework capable of ensuring compliance with regulatory requirements and enabling cross-functional implementation all the way to commercialization.

Leveraging their respective business expertise and achievements, both companies will address these challenges by supporting the relevant companies and organizations in establishing system development frameworks from the initial development stages through post-market operation and maintenance. This collaboration will contribute to improving the quality and speed of SaMD development.

Fujitsu leverages its extensive operational expertise and system development know-how in the healthcare field to develop programmable medical devices and peripheral systems, as well as to provide post-sales system operation and maintenance. Furthermore, in response to customer needs, Fujitsu offers the Healthcare Personal Service Platform, a health and medical information management infrastructure enabling secure and reliable management of personal information.

DT-Axis has a proven track record of obtaining manufacturing and marketing approval for programmable medical devices developed by outsourcing manufacturing to Fujitsu. In system development for programmable medical devices, DT-Axis collaborates with Fujitsu to support smoother design, development, and operation processes, with a focus on approval applications and sales readiness.

Going forward, both companies will continue to explore the establishment of a SaMD distribution platform for the relevant organizations and companies, alongside their SaMD development support. Through this, they aim to build an ecosystem that provides one-stop support from SaMD development to distribution, thereby contributing to the improvement of people's well-being. 

About Fujitsu

Fujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsu

About DT-Axis

DT-Axis is a licensed medical device company dedicated to bringing scientific innovation into clinical practice. Founded in 2020 and authorized to manufacture and market medical devices, DT-Axis integrates clinical research, regulatory strategy, and product development to translate research outcomes from academia and industry into real-world healthcare solutions. By bridging academic innovation and medical device commercialization, DT-Axis accelerates the delivery of reliable and innovative healthcare technologies. DT-Axis’s mission is to expand access to the care patients and clinicians need through the power of technology.

Press Contacts

Fujitsu Limited
Public and Investor Relations Division
Inquiries

DT-Axis Co., Ltd.
Inquiries

TOKYO, Mar 6, 2026 - (JCN Newswire) - As International Women’s Day prompts renewed focus on women’s health, OMRON Healthcare has released a new Women’s Heart Health Factbook spotlighting an often-overlooked issue: the intersection between menopause, hypertension, and long-term cardiovascular risk.

Why this matters

• An estimated 32% of women aged 30–79 worldwide are living with hypertension.
• Yet only 59% are diagnosed, and just 23% achieve effective blood pressure control.
• That equates to less than a quarter of hypertensive women managing to stabilise their blood pressure.

Cardiovascular disease remains the leading cause of death in women globally, with ischemic heart disease and stroke accounting for the majority of cases. Risk often accelerates during and after menopause, as declining estrogen levels affect vascular health and blood pressure regulation.

Women also face additional life-stage factors that may influence cardiovascular outcomes, including pregnancy-related hypertension and hormonal contraceptive use, underscoring the importance of consistent monitoring across the lifespan.

Expert perspective

"Despite being the leading cause of death for women globally, cardiovascular disease is frequently underdiagnosed and undertreated in women due to longstanding biases in research, clinical guidelines and symptom recognition," said Prof. Alta Schutte, Principal Theme Lead of Cardiac, Vascular and Metabolic Medicine in the Faculty of Medicine and Health at UNSW Sydney, Australia.

"Menopause is not only a major life transition — it is also a cardiovascular turning point,” added Karel Herberigs, Managing Director, OMRON Healthcare EMEA. “Greater awareness and routine monitoring can help close a persistent care gap and support earlier intervention.”

Archanna Mohangoo, Medical Marketing Manager (EMEA), said: “Too often, symptoms such as fatigue, disrupted sleep, or heart palpitations are attributed solely to menopause, when they may in some cases signal underlying conditions such as hypertension or atrial fibrillation (AFib), which can significantly increase stroke and heart disease risk if left undetected. This Factbook aims to encourage women and healthcare providers alike to look more closely at cardiovascular health during this stage of life.”

Potential coverage angles

• The global hypertension care gap in women
• Menopause as a cardiovascular risk inflection point
• Why blood pressure monitoring should remain a priority beyond reproductive years
• The under-recognised burden of heart disease in women
• Prevention and early detection strategies across the lifespan

The full Women’s Heart Health Factbook is available to download from:
https://brandportal.healthcare.omron.com/share/365D593E-78F0-4F35-9C8A589508CB5951/

For interviews, expert commentary, or additional data, please contact:
omronhealthcare-pr@kyodo-pr.co.jp

BOSTON, MA, Feb 17, 2026 - (ACN Newswire) - Bioxytran, Inc. (OTCMKTS: BIXT) (“Bioxytran” or the “Company”), a biotechnology company developing galectin-targeting carbohydrate technologies with applications across infectious disease, metabolic health, and inflammation, today announced that it has entered into a commercial Distribution Agreement with Khoury Medical LTD (“Khoury Medical”), a company focused on the development and commercialization of plant-derived dietary supplements.

Under the agreement, Khoury Medical will commercialize A-SUQAR®, a chewable dietary supplement containing Bioxytran’s proprietary partially hydrolyzed guar gum (PHGG) formulation, in permitted markets in accordance with the Distribution Agreement. The product is marketed as a dietary supplement intended to support healthy post-meal blood sugar levels, consistent with applicable regulatory requirements.

“This agreement represents an important milestone for Bioxytran as we transition from a development-stage organization to a company with recurring commercial revenue,” said David Platt, Chief Executive Officer of Bioxytran. “A-SUQAR® provides real-world market validation of our proprietary carbohydrate-based galectin platform, while preserving our ability to advance higher-value pharmaceutical and antiviral programs.”

Bioxytran’s recent positive Phase 2 clinical results with ProLectin-M, its investigational antiviral candidate, further validate the Company’s proprietary carbohydrate-based galectin platform. The same foundational galectin-targeting science underpins both its pharmaceutical development programs and select nutraceutical applications, demonstrating the breadth of potential applications for this technology.

The Distribution Agreement provides the potential for earned, volume-based marketplace exclusivity, subject to defined purchase thresholds and conditions set forth in the Distribution Agreement. Manufacturing will be performed by Bioxytran’s designated OEM, with regulatory registration, marketing, and distribution execution led by Khoury Medical, allowing Bioxytran to maintain a capital-efficient commercial model while retaining full ownership of its intellectual property.

“This collaboration allows us to bring a differentiated, science-informed product with the potential for broader market expansion, subject to applicable agreements and regulatory requirements,” said Nassar Khoury, CEO of Khoury Medical LTD. “We believe A-SUQAR® addresses a meaningful consumer need, and we look forward to building a successful commercial launch together with Bioxytran.”

Importantly, the agreement is structured to apply solely to non-pharmaceutical dietary products, preserving Bioxytran’s ability to independently advance and partner its technology for pharmaceutical, antiviral, and other clinical development applications.

The parties expect initial commercial shipments to commence following completion of standard launch preparations and are addressing a sizable global market demand for the A-SUQAR Line. 

About Bioxytran, Inc.

Bioxytran, Inc. is a biotechnology company developing carbohydrate-based technologies targeting galectins and related biological pathways. The Company’s platform has potential applications across infectious disease, metabolic health, inflammation, and oncology, with development programs spanning pharmaceutical, nutraceutical, and licensing pathways.

For more information, visit www.bioxytraninc.com.

About A-SUQAR

A-SUQAR is an oral chewable tablet taken before a meal to manage blood sugar and built with Bioxytran IP and Manufacturing expertise.  A-SUQAR slows carbohydrate digestion which prevents sharp blood sugar spikes after meals and addresses the nutraceutical side of Diabetes.

About Khoury Medical LTD

Khoury Medical LTD is a health-focused company dedicated to the development and commercialization of plant-derived dietary supplements. The company partners with innovative technology providers to bring differentiated, science-driven products to market through established consumer and pharmacy channels.

Company Contact:
David Plattdavid.platt@bioxytraninc.com
(617) 510-2539

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the expected commercialization of A-SUQAR®, anticipated benefits of the Distribution Agreement, the Company’s recent Phase 2 clinical results, and Bioxytran’s future business and development plans. Forward-looking statements are generally identified by words such as “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements include these terms. Such statements are subject to significant risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied. These risks include, without limitation, risks related to regulatory compliance, commercialization execution, market acceptance, clinical development, intellectual property protection, financing requirements, and other factors described in Bioxytran’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other filings made from time to time. Bioxytran undertakes no obligation to update or revise any forward-looking statements, except as required under applicable securities laws.